EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Predictive value and accuracy of [18F]FDG PET/CT modified response criteria for checkpoint immunotherapy in patients with advanced melanoma

Narjess Ayati, Zahra Jamshidi-Araghi, Magdalena Hoellwerth, Gregor Schweighofer-Zwink, Wolfgang Hitzl, Peter Koelblinger, Christian Pirich, Mohsen Beheshti

European Journal of Nuclear Medicine and Molecular Imaging · 2023

DOI: 10.1007/s00259-023-06247-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2023. Verfasst von Narjess Ayati und 7 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Melanoma, Metabolic Diseases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Paracelsus Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Immune checkpoint inhibitors (ICIs) are widely used in metastatic melanoma and dramatically alter the treatment of these patients. Given the high cost and potential toxicity, a reliable method for evaluating treatment response is needed. In this study, we assessed tumor response in patients with metastatic melanoma treated with ICIs using three modified response criteria: PET Response Evaluation Criteria for Immunotherapy (PERCIMT), PET Response Criteria in Solid Tumors for up to Five Lesions (PERCIST5), and immunotherapy-modified PET Response Criteria in Solid Tumors for up to Five Lesions (imPERCIST5).

Methods

Ninety-one patients with non-resectable stage IV metastatic melanoma who received ICIs were retrospectively enrolled in this study. Each patient had two [ 18 F]FDG PET/CT scans performed before and after ICI therapy. Responses at the follow-up scan were evaluated according to PERCIMT, PERCIST5, and imPERCIST5 criteria. Patients were classified into four groups: complete metabolic response (CMR), partial metabolic response (PMR), progressive metabolic disease (PMD), and stable metabolic disease (SMD). To assess the “disease control rate,” two groups have been defined based on each criterion: patients with CMR, PMR, and SMD as “disease-controlled group (i.e., responders)” and PMD as the “uncontrolled-disease group (i.e., non-responders)”. The correspondence between metabolic tumor response defined by these criteria and clinical outcome was assessed and compared.

Results

The response and the disease control rates were 40.7% and 71.4%, 41.8% and 50.5%, and 54.9% and 74.7% based on the PERCIMT, PERCIST5, and imPERCIST5 criteria, respectively. PERCIMT and imPERCIST5 showed significantly different disease control rates from that of PERCIST5 ( P < 0.001), whereas it was not significant between PERCIMT and imPERCIST5. Overall survival was significantly longer in the metabolic responder groups than in the non-responder groups based on PERCIMT and PERCIST5 criteria (PERCIMT: 2.48 versus 1.47 years, P = 0.003; PERCIST5: 2.57 versus 1.81 years. P = 0.017). However, according to imPERCIST5 criterion, this difference was not observed ( P = 0.12).

Conclusion

Although the appearance of new lesions can be secondary to an inflammatory response to ICIs and indicative of pseudoprogression, given the higher rate of true progression, the appearance of new lesions should be interpreted deliberately. Of the three assessed modified criteria, PERCIMT appear to provide more reliable metabolic response assessment that correlates strongly with overall patient survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaMetabolic DiseasesHumansPositron Emission Tomography Computed TomographyFluorodeoxyglucose F18IpilimumabRetrospective StudiesRadiopharmaceuticalsImmunotherapy

Stichwörter der Autor:innen

Immune checkpoint inhibitorsImmunotherapyMelanomaPERCIMTPERCIST5imPERCIST5

Substanzen

Fluorodeoxyglucose F18IpilimumabRadiopharmaceuticals

Autor:innen und Institutionen

  • Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Division of Molecular Imaging and Theranostics, Department of Nuclear Medicine, University Hospital Salzburg, Paracelsus Medical University, Muellner Hauptstrasse 48, 5020, Salzburg, Austria.
  • Department of Nuclear Medicine, Shahid Rajaie Cardiovascular, Medical & Research Center, Tehran, Iran.
  • Department of Dermatology, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria.
  • Biostatistics and Publication of Clinical Trial Studies, Research and Innovation Management (RIM), Paracelsus Medical University, Salzburg, Austria.
  • Department of Ophthalmology and Optometry, Paracelsus Medical University, Salzburg, Austria.

Förderung

  • Paracelsus Medical University

Zitieren

APA

Ayati, N., Jamshidi-Araghi, Z., Hoellwerth, M., Schweighofer-Zwink, G., Hitzl, W., Koelblinger, P., Pirich, C., & Beheshti, M. (2023). Predictive value and accuracy of [18F]FDG PET/CT modified response criteria for checkpoint immunotherapy in patients with advanced melanoma. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-023-06247-8

Vancouver

Ayati N, Jamshidi-Araghi Z, Hoellwerth M, Schweighofer-Zwink G, Hitzl W, Koelblinger P, et al. Predictive value and accuracy of [18F]FDG PET/CT modified response criteria for checkpoint immunotherapy in patients with advanced melanoma. European Journal of Nuclear Medicine and Molecular Imaging. 2023. doi:10.1007/s00259-023-06247-8

BibTeX
@article{Ayati2023,
  author = {Ayati, Narjess and Jamshidi-Araghi, Zahra and Hoellwerth, Magdalena and Schweighofer-Zwink, Gregor and Hitzl, Wolfgang and Koelblinger, Peter and Pirich, Christian and Beheshti, Mohsen},
  title = {Predictive value and accuracy of [18F]FDG PET/CT modified response criteria for checkpoint immunotherapy in patients with advanced melanoma},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2023},
  doi = {10.1007/s00259-023-06247-8}
}
Kostenlos starten →